The tools will be tested and validated in 200 patients (including 50 historical datasets) across 3 clinical sites, including a prospective clinical study in 50 patients in the last year of the project. The key innovations in VP2HF that make it likely that the project results will be commercially exploited and have major clinical impact are;

1) all tools to process images and signals, and the obtained statistical and biophysical models, will be integrated into one clinical software platform that can be easily and intuitively used by clinicians and tried out in the prospective clinical study and

2) by utilising a decision tree stratification approach, only the appropriate parts of the tool chain, that will add maximum value to the predictions will be used in individual patients, so that the more resource intensive parts will be used when they will add real value.